SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Al Seib / Los Angeles Times via Getty
Drug Development
Amgen Puts Pressure on Mirati with Phase III Lung Cancer Win
Amgen announced Tuesday that initial Phase III data of Lumakras in KRAS G12C-mutated NSCLC met the primary endpoint of progression-free survival.
August 31, 2022
 · 
3 min read
 · 
Tristan Manalac
Business
With $50M, Vilya’s Peptides Aim to Transcend Cells’ Lipid Membrane
Vilya will use its funds for cutting-edge computational techniques to develop innovative drugs for difficult-to-treat diseases.
August 30, 2022
 · 
2 min read
 · 
Tristan Manalac
Kena Betancur/VIEWpress/Corbis via Getty
Drug Development
Bayer’s Kerendia Shows Competitive Profile in Type 2 Diabetes-Related CKD
Phase III data shows the potential of Bayer’s Kerendia to reduce the risk of all-cause and cardiovascular mortality in type 2 diabetes patients with chronic kidney disease.
August 29, 2022
 · 
2 min read
 · 
Tristan Manalac
VCG via Getty Images
Drug Development
Despite Stumbles, Bayer, BMS & Janssen Moving Forward with XIa Inhibitors
Factor XIa inhibitors developed by Bayer and the duo of BMS and Janssen Pharmaceuticals missed Phase II endpoints in data presented at ESC.
August 29, 2022
 · 
3 min read
 · 
Tristan Manalac
Courtesy of Sundry Photography/Getty Images, Tom B
Deals
Pricing Debate Stalls Merck-Seagen Acquisition Deal
Merck’s bid to buy the cancer-focused Seagen has hit a roadblock after the two companies failed to agree on a price, according to a Bloomberg report.
August 26, 2022
 · 
2 min read
 · 
Tristan Manalac
Photo shows professional holding box of work-relat
Business
Zymergen Cuts 80 More Jobs, Parts Ways with Co-Founder
In an SEC filing, Zymergen revealed it was cutting 80 more jobs and parting with Zach Serber, its co-founder and chief scientific officer.
August 26, 2022
 · 
2 min read
 · 
Tristan Manalac
David L. Ryan/The Boston Globe via Getty Images
Pharm Country
NEJM Study: Omicron Blunts Pfizer’s Paxlovid in Younger Adults
According to a recent study, Pfizer’s Paxlovid appeared to be far more effective at reducing deaths and hospitalizations in older adults than younger patients suffering from the Omicron variant of COVID-19.
August 25, 2022
 · 
3 min read
 · 
Tristan Manalac
Harold Cunningham/Getty Images
Genetown
Novartis Spins Off Sandoz to Maximize Growth of Pharmaceuticals, Biosimilars
Novartis unveiled plans to separate its generics and biosimilars arm, Sandoz, into a standalone entity, allowing both to pursue independent and more business-appropriate growth strategies.
August 25, 2022
 · 
3 min read
 · 
Tristan Manalac
Job Trends
Sonoma, Thermo Fisher Bring Jobs to Seattle, WA & Plainville, MA - Updated
Sonoma Bio announced its plans to erect an 83,000-square-foot operations facility in Seattle, while Thermo Fisher opened a new viral vector manufacturing plant in Massachusetts.
August 24, 2022
 · 
3 min read
 · 
Tristan Manalac
male hands with wrist watch is considered American dollars. Hands holding dollar cash. 1000 dollars in 100 bills in a man's hand close-up on a dark background. hundred
Business
Money on the Move: AdvanCell, eTheRNA, Bluejay and More
Money is now flowing into promising platforms for prostate cancer from AdvanCell, mRNA therapeutics from eTheRNA, hepatitis from Bluejay and more.
August 24, 2022
 · 
5 min read
 · 
Tristan Manalac
Deals
Alcon Strengthens Foothold in Eye Space with $770M Aerie Buy
Alcon announced it is buying out Aerie Pharmaceuticals for about $770 million to gain access to the ophthalmic pharma firm’s open-angle glaucoma and ocular hypertension treatments.
August 23, 2022
 · 
2 min read
 · 
Tristan Manalac
Yichuan Cao/NurPhoto via Getty Images
Business
Elon’s Plan B: Musk Reportedly Explores Synchron Investment
Elon Musk has reportedly gotten in touch with Synchron, a company developing a brain-computer interface (BCI) device, to explore potential investment opportunities, according to a report by Reuters.
August 23, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Sundry Photography/Getty Images
Gilead Scores First Approval for Twice-Yearly HIV Drug in Latest Advance
Gilead’s regulatory win could open the doors for patients with complicated medication histories and for whom viral suppression regimens have become difficult to create.
August 22, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Lundbeck’s Migraine Drug Hits Roadblock in Phase III
Lundbeck revealed that its migraine drug Vyepti failed to demonstrate statistical superiority over placebo at reducing the number of monthly migraine days.
August 19, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Genuv Inc.
Drug Development
Genuv Repurposes Novartis’ Cancer Drug to Treat Alzheimer’s - Updated
South Korea-based Genuv Inc. announced the publication of a preclinical study showing the potential of Mekinist, approved by the FDA for melanoma, in Alzheimer’s disease.
August 18, 2022
 · 
3 min read
 · 
Tristan Manalac
Load More